Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)

Published:2014-02-14 Issue:3 Volume:113 Page:429-436
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Krege Susanne¹,Rexer Heidrun²,vom Dorp Frank³,de Geeter Patrick⁴,Klotz Theodor⁵,Retz Margitte⁶,Heidenreich Axel⁷,Kühn Michael⁸,Kamradt Joern⁹,Feyerabend Susan¹⁰,Wülfing Christian¹¹,Zastrow Stefan¹²,Albers Peter¹³,Hakenberg Oliver¹⁴,Roigas Jan¹⁵,Fenner Martin¹⁶,Heinzer Hans¹⁷,Schrader Mark¹⁸

Affiliation:

1. Department of Urology; Alexianer Hospital Maria Hilf GmbH; Krefeld Germany

2. Institute MeckEvidence; Schwarz Germany

3. Department of Urology; University of Essen; Germany

4. Department of Urology; Klinikum Kassel GmbH; Kassel Germany

5. Department of Urology; Klinikum Weiden; Weiden Germany

6. Department of Urology; University Rechts der Isar; Munich Germany

7. Department of Urology; University of Aachen; Aachen Germany

8. Department of Urology; Klinikum Stendal; Stendal Germany

9. Department of Urology; University Homburg/Saar; Homburg Germany

10. Department of Urology; University Tübingen; Tübingen Germany

11. Department of Urology; University of Münster; Münster Germany

12. Department of Urology; University of Dresden; Dresden Germany

13. Department of Urology; University of Düsseldorf; Düsseldorf Germany

14. Department of Urology; University of Rostock; Rostock Germany

15. Department of Urology; Vivantes Klinikum am Urban; Berlin Germany

16. Department of Haemato-oncology; University of Hannover; Hannover Germany

17. Department of Urology; University of Hamburg; Hamburg Germany

18. Department of Urology; Charite-University; Berlin Germany

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12437/fullpdf

Reference31 articles.

1. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;Maase;J Clin Oncol,2000

2. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group;Bellmunt;J Clin Oncol,2000

3. Seven year update of an EORTC phase III trial of high-dose- intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors;Sternberg;Eur J Cancer,2006

4. Randomized phase III study comparing paclitaxel/ cisplatin/ gemcitabine and gemcitabine/ cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup Study 30987;Bellmunt;J Clin Oncol,2012

5. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer;Chow;Anticancer Res,1997

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in systemic therapy for advanced-stage urothelial carcinoma;Nature Reviews Clinical Oncology;2023-11-09

2. Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials;European Urology Oncology;2023-11

3. Epigenetic Priming and Development of New Combination Therapy Approaches;Urothelial Carcinoma;2023

4. Marine Natural Products — a Vital Source of Novel Biotherapeutics;Current Pharmacology Reports;2022-06-08

5. Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy;Oxidative Medicine and Cellular Longevity;2021-10-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3